Please login to the form below

Not currently logged in
Email:
Password:

ThromboGenics

This page shows the latest ThromboGenics news and features for those working in and with pharma, biotech and healthcare.

NICE backs Novartis/ ThromboGenics’ eye drug

NICE backs Novartis/ ThromboGenics’ eye drug

It is also good news for the drug's original developers ThromboGenics, which sold non-US rights for Jetrea to Novartis in 2012 in a deal worth up to 375m, and ... progressive disease much earlier and as soon as patients start experiencing symptoms such

Latest news

More from news
Approximately 3 fully matching, plus 6 partially matching documents found.

Latest appointments

  • ThromboGenics bolsters leadership team ThromboGenics bolsters leadership team

    Appoints Susan Schneider as CMO and Vinciane Vangeersdaele as CCO. ThromboGenics has strengthened its senior leadership team with the appointment of Susan Schneider, who joins the Belgian biotech as its chief ... Patrik De Haes, chief executive officer,

  • ThromoboGenics appoints Thomas Clay as chairman of the board ThromoboGenics appoints Thomas Clay as chairman of the board

    He moves from his previous position as non-executive director. Belgium-based biotech ThromboGenics has appointed non-executive director Thomas Clay as its new chairman of the board and succeeds Staf ... Clay has been a non-executive director of

More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Personalised medicine: driving a need for greater diversity in clinical trials
Kate Shaw, Innovative Trials' Founder & CEO, investigates one of the biggest challenges facing clinical research today....
Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...